By Fineline Cube Sino Medical Sciences Technology Inc. (SHA: 688108) announced that its independently developed Ghunter Revascularization Device, an intracranial thrombectomy stent, has received regulatory approval from the Turkish Ministry of Health. The clearance extends the device’s international regulatory track record following prior approvals in China and the European Union.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | Turkish Ministry of Health |
| Approval Type | Regulatory approval for market authorization |
| Product | Ghunter Revascularization Device (intracranial thrombectomy stent) |
| Indication | Removal of intracranial large‑vessel blood clots in ischemic stroke within 24 hours of symptom onset |
| Announcement Date | 17 Aug 2026 |
| Prior Clearances | China NMPA registration (Apr 2023); EU CE MDR certification (Feb 2026) |
Device Profile & Mechanism of Action
- Device: Ghunter Revascularization Device, a stent‑based thrombectomy system designed for mechanical retrieval of intracranial thrombi
- Target Vessels: Intracranial large vessels, including the internal carotid artery, M1 and M2 segments of the middle cerebral artery, basilar artery, and vertebral artery
- Treatment Window: Indicated within 24 hours of symptom onset, restoring cerebral blood flow in eligible ischemic stroke patients
- Patient Population: Candidates include patients who are ineligible for or have failed intravenous tissue plasminogen activator (IV t‑PA) therapy
- Intellectual Property: Independently developed by Sino Medical Sciences Technology, supporting the company’s proprietary neurovascular portfolio
Global Regulatory Track Record
| Jurisdiction | Regulatory Body | Status | Date |
|---|---|---|---|
| China | NMPA | Registration certificate granted | Apr 2023 |
| European Union | CE MDR | Certification obtained | Feb 2026 |
| Turkey | Ministry of Health | Regulatory approval obtained | Aug 2026 |
The Turkish approval makes the Ghunter device one of the company’s neurovascular products cleared across three major regulatory jurisdictions, providing a foundation for further international commercialization.
Market Impact & Outlook
- Stroke Landscape: Ischemic stroke caused by large‑vessel occlusion remains a leading cause of death and disability globally; mechanical thrombectomy has become the standard of care for eligible patients, with extended treatment windows broadening the treatable population.
- Differentiated Positioning: A stent retriever indicated across multiple intracranial vessels — including posterior circulation territories such as the basilar and vertebral arteries — with a 24‑hour window addresses a broad clinical need, particularly for patients excluded from IV t‑PA therapy.
- International Expansion Strategy: The sequence of NMPA, CE MDR and Turkish approvals signals a deliberate multi‑market rollout, with Turkey serving as a strategic bridge between European and Middle Eastern neurovascular markets.
- Portfolio Momentum: The clearance strengthens Sino Medical Sciences’ position in the fast‑growing neurointerventional device segment, where demand for locally developed, cost‑competitive alternatives continues to rise.
Forward-Looking Statements
This brief contains forward‑looking statements regarding market opportunity, commercialization plans, and international expansion for the Ghunter Revascularization Device. Actual results may differ due to risks including market adoption, reimbursement dynamics, and competitive developments in the neurovascular device market.-Fineline Info & Tech